Last reviewed · How we verify
Sequence 2 - Treatment D: Controlled Release Pregabalin
At a glance
| Generic name | Sequence 2 - Treatment D: Controlled Release Pregabalin |
|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
|---|
| Modality | Small molecule |
|---|
| Phase | Phase 1 |
|---|
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.